Kiromic BioPharma, Inc. (NASDAQ:KRBP) Investor Notice: Investigation over Possible Violations of Securities Laws

An investigation for investors in Kiromic BioPharma, Inc. (NASDAQ:KRBP) shares over potential securities laws violations by Kiromic BioPharma, Inc. was announced.


San Diego, CA -- (SBWire) -- 04/11/2022 --Kiromic BioPharma, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.

Investors who purchased shares of Kiromic BioPharma, Inc. (NASDAQ: KRBP), have certain options and should contact the Shareholders Foundation at or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Kiromic BioPharma, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Houston, TX based Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors.

On or around October 16, 2020, Kiromic BioPharma, Inc conducted its initial public offering ("IPO"), selling 1.25 million shares of common stock priced at $12.00 per share.

Then, on July 16, 2021, Kiromic BioPharma, Inc disclosed that, following the May 2021 submission of two Investigational New Drug Applications ("INDs") to the U.S. Food and Drug Administration ("FDA") "for the first-in-human off-the-shelf allogeneic CAR-T for Solid Tumors", the "FDA returned with comments on the Company's allogeneic CAR-T products with respect to . . . Tracing of all reagents used in manufacturing . . . Flow chart of manufacturing processes . . . [and] Certificate of Analysis (COA) for the Company's CAR-T products (allogeneic CAR-T)."

Then, on August 13, 2021, Kiromic BioPharma, Inc clarified that the FDA had actually put the INDs on "clinical hold".

Finally, on February 2, 2022, Kiromic BioPharma, Inc disclosed that the Company had commenced an internal investigation based on complaints lodged by its former Chief Financial Officer, who had abruptly departed the Company in October 2021. The internal investigation revealed that the FDA had first informed the Company of the clinical hold on June 16 and June 17, 2021, yet the Company had not disclosed these material facts in its IPO documents. Kiromic BioPharma, Inc admitted that this material omission could subject the Company to liability under the securities laws.

Those who purchased shares of Kiromic BioPharma, Inc. (NASDAQ: KRBP) have certain options and should contact the Shareholders Foundation.

Shareholders Foundation, Inc.
Christopher Clausen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739

About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

Media Relations Contact

Michael Daniels
Shareholders Foundation

View this press release online at: